Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Unknown 5Recruiting 5Completed 5Not yet recruiting 3Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 3Advanced Solid Tumor 3Stomach Neoplasms 2Lung Neoplasms 2Cholangiocarcinoma 2Advanced Lung Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous NSCLC 1Solid Tumor 1SCLC 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1High-Risk Resectable NSCLC 1Gastrointestinal Diseases 1Esophageal Diseases 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

Cisplatin 45Radiotherapy 32Fluorouracil 27Paclitaxel 26Irinotecan 17Docetaxel 16Oxaliplatin 11Carboplatin 10pembrolizumab 9Cetuximab 8tislelizumab 7Surgical Procedures, Operative 7Neoadjuvant Therapy 7Drug Therapy 7Radiation 6Leucovorin 6sintilimab 5Nivolumab 5Immunohistochemistry 5Chemotherapy, Adjuvant 5Capecitabine 5nedaplatin 3durvalumab 3camrelizumab 3S 1 (combination) 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Esophageal Squamous Cell Carcinoma × sintilimab × Clear all
NCT04548440 2025-06-12

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Sun Yat-sen University

Phase 2 Completed
50 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04212598 2024-12-10

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

Wuhan University

Phase 2 Completed
40 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03985046 2024-11-07

Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC

Fudan University

Phase 2 Completed
75 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03748134 2023-10-24

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
746 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

NCT03116152 2021-02-03

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2 Completed
190 enrolled 14 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡